STOCK TITAN

HCA Healthcare Reports First Quarter 2024 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
HCA Healthcare, Inc. (NYSE: HCA) reports strong financial results for the first quarter of 2024, with revenues totaling $17.339 billion, net income of $1.591 billion, and adjusted EBITDA of $3.353 billion. Same facility admissions and emergency room visits increased, while inpatient surgeries rose and outpatient surgeries declined. The balance sheet shows cash and cash equivalents of $1.284 billion, total debt of $40.191 billion, and total assets of $56.962 billion. Cash flows from operating activities amounted to $2.469 billion. The Company repurchased shares and declared a quarterly cash dividend of $0.66 per share. Future dividends are expected to be funded by cash balances and cash flows from operations. The Company reaffirmed its 2024 estimated guidance ranges.
HCA Healthcare, Inc. (NYSE: HCA) ha riportato risultati finanziari forti per il primo trimestre del 2024, con entrate pari a 17,339 miliardi di dollari, un utile netto di 1,591 miliardi di dollari e un EBITDA rettificato di 3,353 miliardi di dollari. Si è registrato un aumento delle ammissioni nelle stesse strutture e delle visite al pronto soccorso, mentre le chirurgie ospedaliere sono aumentate e quelle ambulatoriali sono diminuite. Il bilancio mostra disponibilità liquide per 1,284 miliardi di dollari, un debito totale di 40,191 miliardi di dollari e attivi totali per 56,962 miliardi di dollari. I flussi di cassa dalle attività operative sono stati di 2,469 miliardi di dollari. La società ha riacquistato azioni e dichiarato un dividendo trimestrale in contanti di 0,66 dollari per azione. Si prevede che i dividendi futuri saranno finanziati dalle disponibilità di cassa e dai flussi di cassa operativi. La società ha confermato le stime per le previsioni del 2024.
HCA Healthcare, Inc. (NYSE: HCA) informa de resultados financieros sólidos para el primer trimestre de 2024, con ingresos que suman $17.339 mil millones, beneficio neto de $1.591 mil millones y un EBITDA ajustado de $3.353 mil millones. Las admisiones en las mismas instalaciones y las visitas a urgencias aumentaron, mientras que las cirugías de ingreso subieron y las ambulatorias disminuyeron. El balance general indica que tiene efectivo y equivalentes de efectivo de $1.284 mil millones, una deuda total de $40.191 mil millones y activos totales de $56.962 mil millones. Los flujos de caja de actividades operativas alcanzaron $2.469 mil millones. La compañía recompró acciones y declaró un dividendo en efectivo trimestral de $0.66 por acción. Se espera que los futuros dividendos se financien con saldos de efectivo y flujos de caja operativos. La compañía reafirmó sus rangos de guía estimados para 2024.
HCA 헬스케어, Inc. (NYSE: HCA)는 2024년 첫 분기에 강한 재무 결과를 보고했습니다. 총 수입은 173억 3,900만 달러, 순수익은 15억 9,100만 달러, 조정 EBITDA는 33억 5,300만 달러였습니다. 동일 시설 입원과 응급실 방문이 증가했으며, 입원 수술은 증가했지만 외래 수술은 감소했습니다. 대차대조표에 따르면 현금 및 현금성 자산은 12억 8,400만 달러, 총 부채는 401억 9,100만 달러, 총 자산은 569억 6,200만 달러입니다. 운영 활동으로부터의 현금 흐름은 24억 6,900만 달러였습니다. 회사는 주식을 매입하고 주당 0.66달러의 분기 현금 배당을 선언했습니다. 미래의 배당금은 현금 잔고와 운영 활동으로부터의 현금 흐름으로 조달될 것으로 예상됩니다. 회사는 2024년 예상 지침 범위를 재확인했습니다.
HCA Healthcare, Inc. (NYSE : HCA) annonce d'excellents résultats financiers pour le premier trimestre de 2024, avec un chiffre d'affaires de 17,339 milliards de dollars, un bénéfice net de 1,591 milliard de dollars et un EBITDA ajusté de 3,353 milliards de dollars. Les admissions dans les mêmes établissements ainsi que les visites aux urgences ont augmenté, tandis que les chirurgies en hospitalisation ont augmenté et les chirurgies en ambulatoire ont diminué. Le bilan affiche une trésorerie et des équivalents de trésorerie de 1,284 milliard de dollars, une dette totale de 40,191 milliards de dollars et des actifs totaux de 56,962 milliards de dollars. Les flux de trésorerie provenant des activités opérationnelles se sont élevés à 2,469 milliards de dollars. La société a racheté des actions et déclaré un dividende trimestriel en espèces de 0,66 dollar par action. Les futurs dividendes devraient être financés par les soldes de trésorerie et les flux de trésorerie provenant des opérations. La société a réaffirmé ses prévisions estimées pour 2024.
HCA Healthcare, Inc. (NYSE: HCA) meldet starke Finanzergebnisse für das erste Quartal 2024 mit einem Umsatz von 17,339 Milliarden Dollar, einem Nettoeinkommen von 1,591 Milliarden Dollar und einem bereinigten EBITDA von 3,353 Milliarden Dollar. Die Aufnahmen in denselben Einrichtungen sowie die Notaufnahmebesuche nahmen zu, während stationäre Operationen stiegen und ambulante Operationen zurückgingen. Die Bilanz weist liquide Mittel und Bargeldäquivalente von 1,284 Milliarden Dollar, eine Gesamtverschuldung von 40,191 Milliarden Dollar und Gesamtaktiva von 56,962 Milliarden Dollar aus. Der Cashflow aus betrieblichen Tätigkeiten belief sich auf 2,469 Milliarden Dollar. Das Unternehmen kaufte Aktien zurück und erklärte eine vierteljährliche Bardividende von 0,66 Dollar pro Aktie. Zukünftige Dividenden sollen durch Barguthaben und operative Cashflows finanziert werden. Das Unternehmen bestätigte seine geschätzten Prognosespannen für 2024.
Positive
  • Revenues totaled $17.339 billion for the first quarter of 2024, compared to $15.591 billion in the same period of 2023.
  • Net income attributable to HCA Healthcare, Inc. was $1.591 billion, or $5.93 per diluted share, up from $1.363 billion, or $4.85 per diluted share, in the first quarter of 2023.
  • Adjusted EBITDA for the first quarter of 2024 was $3.353 billion, compared to $3.172 billion in the first quarter of 2023.
  • Same facility admissions increased by 6.2 percent, and same facility equivalent admissions increased by 5.2 percent in the first quarter of 2024.
  • Cash and cash equivalents were $1.284 billion, total debt stood at $40.191 billion, and total assets were $56.962 billion as of March 31, 2024.
  • Cash flows from operating activities totaled $2.469 billion in the first quarter of 2024.
  • The Company repurchased 3.894 million shares of its common stock at a cost of $1.180 billion in the first quarter of 2024.
  • A quarterly cash dividend of $0.66 per share on the Company's common stock was declared, to be paid on June 28, 2024.
  • The Company reaffirmed its 2024 estimated guidance ranges issued in January 2024.
Negative
  • None.

Insights

HCA Healthcare's first quarter results demonstrate robust growth in both revenue and net income, indicating a strong operational performance. The increase in revenue from $15.591 billion to $17.339 billion represents a notable year-over-year rise, driven by an uptick in facility admissions and emergency room visits. This suggests that HCA is effectively capturing market demand and enhancing patient throughput.

From an investor's perspective, the growth in net income from $1.363 billion to $1.591 billion is impressive, as it translates to a higher earnings per share, moving from $4.85 to $5.93. Such performance could be seen as indicative of strong management execution and potentially, greater shareholder return, evidenced by the quarterly cash dividend of $0.66 per share.

However, the dip in outpatient surgeries alongside rising capital expenditures, now at $1.118 billion, requires careful monitoring. Increased capital outlays, while contributing to future growth, could exert pressure on short-term cash reserves. Nonetheless, the company's share repurchase activity, totaling $1.180 billion, underscores confidence in its intrinsic value and management's commitment to returning value to shareholders.

The company's reaffirmed guidance for 2024 suggests stability and confidence in their operations despite external uncertainties such as economic conditions and inflation. Investors should, however, remain cognizant of the inherent risks associated with the healthcare industry, including regulatory changes and payer mix fluctuations.

It is important to assess the governance implications of the reported financial results. The Board's decision to declare a quarterly dividend reflects a stable governance strategy and a prudent balance between reinvesting in the company and providing shareholder returns. The ongoing stock repurchase program further indicates a board-level initiative to optimize capital allocation.

Attention should also be given to the Board's discretion regarding future dividends. This discretionary approach allows flexibility to adapt to changing financial and economic landscapes, which can safeguard the company's financial health in the long run. Nonetheless, investors must weigh the potential impact of such discretionary policies on future dividend reliability and the implications for income-focused investment strategies.

Investors should also be considerate of the level of debt on the balance sheet. With total debt at $40.191 billion and cash flows from operations encouraging at $2.469 billion, the current leverage does not appear to be a pressing concern. Nevertheless, the ratio of debt to EBITDA and the coverage of interest expenses are critical metrics that need continuous monitoring, especially in a rising interest rate environment.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2024.

Key first quarter metrics (all percentage changes compare 1Q 2024 to 1Q 2023 unless otherwise noted):

  • Revenues totaled $17.339 billion
  • Net income attributable to HCA Healthcare, Inc. totaled $1.591 billion, or $5.93 per diluted share
  • Adjusted EBITDA totaled $3.353 billion
  • Cash flows from operating activities totaled $2.469 billion
  • Same facility admissions increased 6.2 percent while same facility equivalent admissions increased 5.2 percent

“The strong fundamentals we saw in our business this past year continued into the first quarter of 2024. This momentum generated strong financial results that were driven primarily by broad-based volume growth,” said Sam Hazen, Chief Executive Officer of HCA Healthcare.

Revenues in the first quarter of 2024 totaled $17.339 billion, compared to $15.591 billion in the first quarter of 2023. Net income attributable to HCA Healthcare, Inc. totaled $1.591 billion, or $5.93 per diluted share, compared to $1.363 billion, or $4.85 per diluted share, in the first quarter of 2023. Results for the first quarter of 2024 include gains on sales of facilities of $201 million, or $0.57 per diluted share, primarily related to the sale of a hospital facility in California. Results for the first quarter of 2023 include losses on sales of facilities of $15 million, or $0.08 per diluted share. During the first quarter of 2023, we recorded $145 million of revenues, or $0.40 per diluted share, related to resolving certain disputed claims from prior years with a commercial payer.

For the first quarter of 2024, Adjusted EBITDA totaled $3.353 billion, compared to $3.172 billion in the first quarter of 2023. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions increased 6.2 percent while same facility equivalent admissions increased 5.2 percent in the first quarter of 2024, compared to the prior year period. Same facility emergency room visits increased 7.2 percent in the first quarter of 2024, compared to the prior year period. Same facility inpatient surgeries increased 1.7 percent, and same facility outpatient surgeries declined 2.1 percent in the first quarter of 2024, compared to the same period of 2023. Same facility revenue per equivalent admission increased 3.5 percent in the first quarter of 2024, compared to the first quarter of 2023.

Balance Sheet and Cash Flows from Operations

As of March 31, 2024, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $1.284 billion, total debt of $40.191 billion, and total assets of $56.962 billion. During the first quarter of 2024, capital expenditures totaled $1.118 billion, excluding acquisitions. Cash flows provided by operating activities in the first quarter of 2024 totaled $2.469 billion, compared to $1.803 billion in the first quarter of 2023.

During the first quarter of 2024, the Company repurchased 3.894 million shares of its common stock at a cost of $1.180 billion. The Company had $5.595 billion remaining under its repurchase authorization as of March 31, 2024. As of March 31, 2024, the Company had $7.987 billion of availability under its credit facilities.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share on the Company’s common stock. The dividend will be paid on June 28, 2024 to stockholders of record at the close of business on June 14, 2024.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition, results of operations, and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

2024 Guidance

Today, the Company reaffirmed its 2024 estimated guidance ranges issued on January 30, 2024.

The Company’s 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Earnings Conference Call

HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.

About the Company

As of March 31, 2024, HCA operated 188 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2024, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry); changes in revenues due to declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions (including as a result of geopolitical disruptions); and the impact of potential federal government shutdowns, (2) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including, but not limited to, proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, attain expected levels of patient volumes and revenues, and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs or state directed payments, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, including but not limited to developments related to COVID-19, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of actual and potential cybersecurity incidents or security breaches, including the data security incident disclosed in July 2023, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, physical risks from climate change or similar events beyond our control, (24) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, (25) the results of our efforts to use technology and resilience initiatives, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2023 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
First Quarter
Unaudited
(Dollars in millions, except per share amounts)
   
   
   

2024

 

2023

 

Amount

Ratio

 

Amount

Ratio

 
   
Revenues

$17,339

 

100.0

%

$15,591

100.0

 

%

   
Salaries and benefits

7,707

 

44.4

 

7,084

45.4

 
Supplies

2,671

 

15.4

 

2,423

15.5

 
Other operating expenses

3,606

 

20.9

 

2,894

18.7

 
Equity in losses of affiliates

2

 

-

 

18

0.1

 
Depreciation and amortization

795

 

4.5

 

756

4.8

 
Interest expense

512

 

3.0

 

479

3.1

 
Losses (gains) on sales of facilities

(201

)

(1.2

)

15

0.1

 
   

15,092

 

87.0

 

13,669

87.7

 
   
Income before income taxes

2,247

 

13.0

 

1,922

12.3

 
   
Provision for income taxes

445

 

2.6

 

379

2.4

 
   
Net income

1,802

 

10.4

 

1,543

9.9

 
   
Net income attributable to noncontrolling interests

211

 

1.2

 

180

1.2

 
   
Net income attributable to HCA Healthcare, Inc.

$1,591

 

9.2

 

$1,363

8.7

 
   
Diluted earnings per share

$5.93

 

$4.85

 
   
Shares used in computing diluted earnings per share (millions)

268.016

 

280.961

 
   
Comprehensive income attributable to HCA Healthcare, Inc.

$1,583

$1,383

 
 
 
HCA Healthcare, Inc.
Condensed Consolidated Balance Sheets
Unaudited
(Dollars in millions)
 
 
 
March 31, December 31,

2024

2023

 
ASSETS
Current assets:
Cash and cash equivalents

$1,284

 

$935

 

Accounts receivable

10,044

 

9,958

 

Inventories

1,903

 

2,021

 

Other

2,051

 

2,013

 

15,282

 

14,927

 

 
Property and equipment, at cost

59,440

 

58,548

 

Accumulated depreciation

(31,344

)

(30,833

)

28,096

 

27,715

 

 
Investments of insurance subsidiaries

471

 

477

 

Investments in and advances to affiliates

736

 

756

 

Goodwill and other intangible assets

9,967

 

9,945

 

Right-of-use operating lease assets

2,211

 

2,207

 

Other

199

 

184

 

 

$56,962

 

$56,211

 

 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

$4,735

 

$4,233

 

Accrued salaries

1,759

 

2,127

 

Other accrued expenses

3,619

 

3,871

 

Long-term debt due within one year

3,028

 

2,424

 

13,141

 

12,655

 

 
Long-term debt, less debt issuance costs and discounts of $381 and $333

37,163

 

37,169

 

Professional liability risks

1,571

 

1,557

 

Right-of-use operating lease obligations

1,912

 

1,903

 

Income taxes and other liabilities

1,905

 

1,867

 

 
Stockholders' equity:
Stockholders' deficit attributable to HCA Healthcare, Inc.

(1,615

)

(1,774

)

Noncontrolling interests

2,885

 

2,834

 

1,270

 

1,060

 

$56,962

 

$56,211

 

 
 
HCA Healthcare, Inc.
Condensed Consolidated Statements of Cash Flows
First Quarter
Unaudited
(Dollars in millions)
 
 
 

2024

 

2023

 
Cash flows from operating activities:
Net income

$1,802

 

$1,543

 

Adjustments to reconcile net income to net cash provided by operating activities:
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable

(90

)

238

 

Inventories and other assets

77

 

(214

)

Accounts payable and accrued expenses

(517

)

(1,066

)

Depreciation and amortization

795

 

756

 

Income taxes

444

 

372

 

Losses (gains) on sales of facilities

(201

)

15

 

Amortization of debt issuance costs and discounts

9

 

9

 

Share-based compensation

87

 

77

 

Other

63

 

73

 

 
Net cash provided by operating activities

2,469

 

1,803

 

 
 
Cash flows from investing activities:
Purchase of property and equipment

(1,118

)

(1,197

)

Acquisition of hospitals and health care entities

(96

)

(115

)

Sales of hospitals and health care entities

310

 

165

 

Change in investments

2

 

(13

)

Other

(1

)

9

 

 
Net cash used in investing activities

(903

)

(1,151

)

 
 
Cash flows from financing activities:
Issuances of long-term debt

4,483

 

-

 

Net change in revolving credit facilities

(1,880

)

1,240

 

Repayment of long-term debt

(2,066

)

(550

)

Distributions to noncontrolling interests

(152

)

(187

)

Payment of debt issuance costs

(40

)

(3

)

Payment of dividends

(185

)

(175

)

Repurchase of common stock

(1,180

)

(846

)

Other

(196

)

(204

)

 
Net cash used in financing activities

(1,216

)

(725

)

 
Effect of exchange rate changes on cash and cash equivalents

(1

)

7

 

 
Change in cash and cash equivalents

349

 

(66

)

Cash and cash equivalents at beginning of period

935

 

908

 

 
 
Cash and cash equivalents at end of period

$1,284

 

$842

 

 
 
Interest payments

$538

 

$574

 

Income tax payments, net

$1

 

$7

 

 
 
HCA Healthcare, Inc.
Operating Statistics
 
 
 
First Quarter

2024

 

2023

 
Operations:
Number of Hospitals

188

 

180

 

Number of Freestanding Outpatient Surgery Centers*

121

 

126

 

Licensed Beds at End of Period

49,724

 

48,891

 

Weighted Average Beds in Service

42,564

 

41,684

 

 
Reported:
Admissions

560,869

 

525,235

 

% Change

6.8

%

Equivalent Admissions

981,521

 

916,535

 

% Change

7.1

%

Revenue per Equivalent Admission

$ 17,666

 

$ 17,011

 

% Change

3.9

%

Inpatient Revenue per Admission

$ 18,923

 

$ 17,828

 

% Change

6.1

%

 
Patient Days

2,781,596

 

2,637,903

 

% Change

5.4

%

Equivalent Patient Days

4,867,793

 

4,603,141

 

% Change

5.7

%

 
Inpatient Surgery Cases

133,398

 

130,460

 

% Change

2.3

%

Outpatient Surgery Cases

252,835

 

255,971

 

% Change

-1.2

%

 
Emergency Room Visits

2,428,914

 

2,252,669

 

% Change

7.8

%

 
Outpatient Revenues as a
Percentage of Patient Revenues

36.9

%

37.7

%

Average Length of Stay (days)

4.959

 

5.022

 

 
Occupancy**

75.2

%

74.0

%

 
Same Facility:
Admissions

555,681

 

523,458

 

% Change

6.2

%

Equivalent Admissions

960,772

 

913,434

 

% Change

5.2

%

Revenue per Equivalent Admission

$ 17,569

 

$ 16,981

 

% Change

3.5

%

Inpatient Revenue per Admission

$ 18,964

 

$ 17,796

 

% Change

6.6

%

 
Inpatient Surgery Cases

132,274

 

130,010

 

% Change

1.7

%

Outpatient Surgery Cases

247,721

 

253,023

 

% Change

-2.1

%

 
Emergency Room Visits

2,400,190

 

2,238,063

 

% Change

7.2

%

 
 
* Excludes freestanding endoscopy centers (24 centers at March 31, 2024 and 22 centers at March 31, 2023).
** Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service.
 
 
Supplemental Non-GAAP Disclosures
Operating Results Summary
(Dollars in millions, except per share amounts)
 
 
 
First Quarter

2024

 

2023

 
Revenues

$17,339

 

$15,591

 

 
Net income attributable to HCA Healthcare, Inc.

$1,591

 

$1,363

 

Losses (gains) on sales of facilities (net of tax)

(154

)

22

 

Net income attributable to HCA Healthcare, Inc., as adjusted (a)

1,437

 

1,385

 

Depreciation and amortization

795

 

756

 

Interest expense

512

 

479

 

Provision for income taxes

398

 

372

 

Net income attributable to noncontrolling interests

211

 

180

 

 
Adjusted EBITDA (a)

$3,353

 

$3,172

 
Adjusted EBITDA margin (a)

19.3

%

20.3

%

 
Diluted earnings per share:
Net income attributable to HCA Healthcare, Inc.

$5.93

 

$4.85

 

Losses (gains) on sales of facilities

(0.57

)

0.08

 

Net income attributable to HCA Healthcare, Inc., as adjusted (a)

$5.36

 

$4.93

 
Shares used in computing diluted earnings per share (millions)

268.016

 

280.961

 
______________________

(a)

Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). These non-GAAP financial measures are adjusted to exclude losses (gains) on sales of facilities and losses on retirement of debt. We believe net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

 

 

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that adjustments, including losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

 

 

Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 
 
HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
2024 Operating Results Forecast
(Dollars in millions, except per share amounts)
 
 
For the Year Ending
December 31, 2024
Low High
 
Revenues

$67,750

$70,250

 
Net income attributable to HCA Healthcare, Inc. (a)

$5,200

$5,600

Depreciation and amortization

3,200

3,270

Interest expense

1,985

2,040

Provision for income taxes

1,615

1,740

Net income attributable to noncontrolling interests

850

900

 
Adjusted EBITDA (a) (b)

$12,850

$13,550

 
Diluted earnings per share:
Net income attributable to HCA Healthcare, Inc.

$19.70

$21.20

 
Shares used in computing diluted earnings per share (millions)

264.000

264.000

 
The Company's forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.
______________________

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

 

 

 

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

 

 

 

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

INVESTOR CONTACT:

Frank Morgan

615-344-2688

MEDIA CONTACT:

Harlow Sumerford

615-344-1851

Source: HCA Healthcare

HCA Healthcare, Inc.

NYSE:HCA

HCA Rankings

HCA Latest News

HCA Stock Data

79.98B
181.11M
28.42%
63.63%
1.17%
Medical Care Facilities
Services-general Medical & Surgical Hospitals, Nec
Link
United States of America
NASHVILLE